Peptide Development Platform

Our peptide development platform allows for rapid and systematic identification of MHCI/II bound peptide candidates for the development of new vaccines, therapeutic antibodies and CAR T cells.

We work with biopharmaceutical companies interested in developing antibodies or CAR T for their TAAs or antigen.

IntelliStem has an end-to-end platform for any company interested in developing Antibodies. From the initial sequence of the antigen all the way until the delivery of a humanized antibody.